We have performed a long-term study into the use of a lipophilic amino-acid dendrimer to deliver an anti-vascular endothelial growth factor (VEGF) oligonucleotide (ODN-1) into the eyes of rats and inhibit laser-induced choroidal neovascularization (CNV). In addition, the uptake, distribution and retinal tolerance of the dendrimer plus oligonucleotide conjugates were examined. Analysis of fluorescein angiograms of laser photocoagulated eyes revealed that dendrimer plus ODN-1 significantly inhibited (Po0.05) the development of CNV for 4-6 months by up to 95% in the initial stages. Eyes similarly injected with ODN-1 alone showed no significant difference (P40.05) in mean severity score at 2 months (2.8670.09), 4 months (2.1570.17) or 6 months (2.770.12) compared to the vehicle-injected controls. Furthermore, we showed that intravitreally injected ODN-1 tagged with 6-fam was absorbed by a wide area of the retina and penetrated all of the retinal cell layers to the retinal pigment epithelium. Ophthalmological examinations indicated that the dendrimers plus ODN-1 conjugates were well tolerated in vivo, which was later confirmed using immunohistochemistry, which showed no observable increase in antigens associated with inflammation. We conclude that the use of such dendrimers may provide a viable mechanism for the delivery of therapeutic oligonucleotides for the treatment of angiogenic eye diseases. Gene Therapy (2005) 12, 1544-1550.
Introduction
Overexpression of vascular endothelial growth factor (VEGF) has been implicated in a number of diseases associated with angiogenesis including age-related macular degeneration (AMD), 1 diabetic retinopathy (DR) 2, 3 and tumor development. 4 Several gene therapies are being developed and trialed for the control of such diseases and much of the technology centers on the inhibition of VEGF and consequently the inhibition of angiogenesis, a process that is essential to disease progression. These therapies include gene transfer and endogenous expression of recombinant proteins, 5, 6 use of pegalated aptamers to bind and inhibit activity of excess VEGF 7 and oligonucleotide gene therapy. [8] [9] [10] Previously, we have reported on the discovery and use of a sense oligonucleotide (ODN-1) that is complimentary to a section of sequence in the 5 0 untranslated region of VEGF, for the inhibition of VEGF expression both in vitro and in vivo. We subsequently tested the efficacy of ODN-1 in reducing the extent of laser photocoagulation induced choroidal neovascularisation (CNV) in a rodent model. 11 However, like most other genetic-based therapies, delivery and longevity of the effects remain a limiting factor. More recently, we described the synthesis and use of lipophilic amino-acid dendrimers that enhanced the delivery of ODN-1 into the retinal tissue of rats. 12, 13 In addition, the data from this earlier study suggested that the dendrimers served as a protective agent against the effects of nucleases while enabling ODN-1 to interact with its target site within the gene.
In this study, we extend the initial research of Marano et al 12 and examine the issue of longevity of dendrimer plus ODN-1 conjugates. The duration of the study was extended to 6 months, and the efficacy of the conjugates to inhibit laser-induced CNV was examined at various time points. In addition, the uptake and distribution was assessed.
Results

CNV inhibition
The laser photocoagulation CNV model is an effective means of analyzing the longevity and bioavailability of an antiangiogenic compound in the eye. Following injection with ODN-1, dendrimer and dendrimer conjugated to ODN-1, laser photocoagulation was performed at 2, 4 and 6 months. The lesions were confirmed using color fundus photography (CFP) (Figure 1a , c, e and g) where typically they appear as white patches. The progress of CNV associated with the lesions were initially monitored and documented in vivo using fluorescein angiography (FA) (Figure 1b , d, f and h) and subsequently post mortem by measuring the choroidal thickness at the lesion and nonlesion sites and calculating the B/C ratio.
FA. In eyes treated with dendrimer alone, leakage due to CNV determined by clinical examination were determined to be severe at all examination time points. It was decided to cease data collection of this group after 4 months and use the available information as control data. In these eyes, CNV appears as densely colored patches due to leakage of fluorescein from the newly developing blood vessels ( Figure 1b ) and remains consistent throughout the study period. The introduction of lesions 2 months post injection revealed that ODN-1, when injected alone, had no observable inhibitory effect on the extent of CNV development when compared to the controls. Subsequent examinations of laser lesions administered 4 and 6 months post injection indicated that this result remained unchanged in eyes injected with ODN-1 alone (data not shown). Conversely, in eyes injected with dendrimer plus ODN-1, the severity of CNV development viewed using FA appeared greatly reduced at 2 months (Figure 1d) . However, at 4 months, CNV development appeared more severe (Figure 1e ) than that seen at 2 months, and at 6 months, no discernable difference could be distinguished from the controls (Figure 1g ). These observations were confirmed using the densitometry method to calculate the extent of CNV and assigned a mean severity score to each lesion in the FAs (Figure 2 ). The mean severity score calculated for eyes injected with ODN-1 alone (2.8670.09, 2.1570.17 and 2.770.12, respectively) did not differ significantly (P40.01) at 2, 4 or 6 months, from the scores calculated for the controls. However, the mean CNV severity score for eyes injected with dendrimer plus ODN-1 was significantly (Po0.05) lower at both 2 months (0.1870.12) and 4 months (1.3970.17) post injection compared to the controls and eyes injected with ODN-1 alone at the same time. By 6 months, the mean severity score (270.18) was no longer considered significant (P40.05) compared to all other groups. These data indicate that there was a progressive decrease in the ability of dendrimer plus ODN-1 to inhibit CNV. B/C ratio. A second method that measures the B/C ratio (B refers to the maximum thickness of the lesion and C is the thickness of the normal RPE-choroidal layers adjacent to the lesion) was used to determine the extent of CNV. Unlasered, the choroidal bed of the retina Using the densitometry method, the extent of CNV was calculated and statistically analyzed. When injected alone, ODN-1 had no significant effect (P40.05) on the development of CNV compared to the dendrimer-treated control eyes at each time point measured. However, CNV was significantly reduced in eyes injected with dendrimer plus ODN-1 at the 2-and 4-month time points (*Po0.05). By 6 months, this effect was no longer considered significant (P40.05).
Dendrimer delivery of oligonucleotides into eye's RJ Marano et al possesses a near uniform thickness (Figure 3a) . However, introduction of a laser lesion produces a thickening in this area (Figure 3b and c). This thickening appeared less pronounced in eyes injected with dendrimer plus ODN-1 ( Figure 3b ) compared to eyes injected with ODN-1 alone (Figure 3c ), which also exhibited the formation of blood vessels within the retinal cell layers extending from the choroid. Measurement of the thickness ratio of lesions in eyes from each group of injected rats confirmed a significant reduction of B/C in rats treated with dendrimer plus ODN-1 (Po0.05) compared to all other groups at 2 and 4 months post injection (Figure 4 ), but not at 6 months, supporting the data obtained from the angiograms. The control data consisted of pooled results from all lasered eyes treated with dendrimer alone at all time points.
Uptake and distribution
Uptake and distribution of ODN-1 6-FAM and dendrimer plus ODN-1 conjugate were monitored using fluorescence microscopy. Distribution was initially examined using whole mounts of retinal tissue, which revealed that at 2 weeks post injection, ODN-1 6-FAM and dendrimer plus ODN-1 6-FAM were detected over a wide area of the retina (Figure 5a ). Frozen sections were subsequently processed by initially incubating in Sudan black to quench background signal resulting from autofluorescence. In uninjected control eyes, autofluorescence was eliminated in all retinal cell layers with some minor fluorescence still present in the sclera (Figure 5b ). In eyes injected with ODN-1 6-FAM alone, no fluorescent signal could be detected following treatment with Sudan black from 2 months post injection onwards. However, in eyes injected with dendrimer plus ODN-1 6-FAM , a fluorescent signal could be seen in the retinal pigment (RP) layer in addition to the outer nuclear layer, inner nuclear layer and the ganglion cell layer (Figure 5c and d) of eyes enucleated at 2 and 4 months post injection. At 4 months, the signal had become more centralized within the RP cells while in other layers, the signal appeared to be reduced in intensity and distribution. In addition, it should be noted that the signal appeared to be localized to the nuclei of cells and absent from the cytoplasmic compartment. No signal was evident by 6 months post injection with dendrimer plus ODN-1 .
Toxicity
Ophthalmological examinations performed at regular intervals revealed no adverse effects resulting from the Figure 3 Histological analysis of H&E-stained paraffin-embedded eyes. In a normal section (a), the choroid possesses a uniform thickness. A representative section of a mild lesion (b) shows thickening at the lesion site. In a severe lesion (c), the thickening is more pronounced and a magnified section (d) shows the presence of blood vessels within the retinal cell layers (black arrowheads). The B/C ratio was determined from maximum thickness of session (B) and thickness of adjacent normal RPEchoroid (C). Figure 4 Comparison of B/C ratios from injected eyes. The control consisted of the pooled B/C ratios of eyes injected with dendrimer alone. In eyes injected with dendrimer plus ODN-1, analysis of the B/C ratios indicates a significant decrease (Po0.05) in CNV at the 2 and 4 month time points (*Po0.05) compared to the control and all other treatment groups. However, no effect was calculated for eyes injected with ODN-1 alone compared to the control group. Dendrimer delivery of oligonucleotides into eye's RJ Marano et al injection of either ODN-1, dendrimer or a conjugate of the two compounds. In addition, analysis of sectioned eyes using immunohistochemistry revealed no observable increase in the presence on inflammation-specific components such as macrophages' indicating that the compounds were well tolerated at the concentrations used.
Discussion
At present, the most common forms of treatments for blinding eye diseases associated with CNV include laser photocoagulation, photodynamic therapy, or a combination of both. However, the effects of these treatments are limited, varied and generally do not result in improved eyesight. The major contributing factor underlying the proliferation of choroidal blood vessels is the upregulation of VEGF, where increased levels have been found in the vitreous of patients suffering from AMD. 2 Recent research has, therefore, centered on the control of VEGF expression or on limiting its biological activity. [14] [15] [16] ODNs have recently come to the forefront of technology for the control of gene expression but some issues still need to be addressed. The most prominent of these issues are longevity of the ODN in situ coupled with an efficient delivery mechanism.
Previously in our laboratories, we have sought to overcome both of these problems with the introduction of a dendrimer-mediated delivery system for ODN-1, an anti-VEGF sense oligonucleotide, initially in vitro and subsequently in vivo. 12, 13 In this instance, the dendrimer under investigation provided the conjugated ODN-1 a high degree of protection against nucleases in addition to effecting efficient delivery to the target site. However, the effective time of this protection, and its comparison to other methods of improving longevity had not yet been fully explored. In this paper, we report on a follow up, long-term study of these previous results in an attempt to address these issues. Rats were injected in both eyes with either ODN-1 or ODN-1 conjugated to a previously described dendrimer. 12 CNV was induced using the laser photocoagulation method 17 at 2, 4 and 6 months post injection. The eyes were subsequently examined using CFP, FA, histology and immunohistochemistry and evaluated for the extent of neovascularization in addition to uptake, distribution and toxicity of both ODN-1 alone and dendrimer plus ODN-1.
The densitometry technique performed on the fluorescein angiograms proved effective in calculating the extent of laser-induced CNV. These data were later supported by the B/C ratio measurements on H&E-stained paraffin sections. In the groups of rats injected with ODN-1 alone, no significant reduction (P40.05) in CNV development compared to the controls could be detected at any of the time points. This result was not surprising, as the ODN used in this study possessed a native phosphodiester backbone, which is highly susceptible to the effects of nucleases. However, in the groups that were injected with dendrimer plus ODN-1, the level of CNV development was significantly reduced (Po0.05) at the initial 2-month period compared to the controls. This result was in accordance with our previous study 12 and indicates that the dendrimer not only protects ODN-1 from the effects of nucleases but also mediates its delivery to the site of activity. Further evaluation at the 4-month time point later revealed that the level of CNV inhibition was reduced but still statistically significant (Po0.05). However, by the 6-month time point, the level of inhibition was no longer considered statistically significant compared to the control. This suggests that the protection afforded by the dendrimer was not permanent, due to either ODN-1 being degraded by nucleases or the dendrimer plus ODN-1 being metabolized in some other way, leading to its reduced presence within the tissue, and hence to a lowered capacity to inhibit CNV.
The effect of diminishing effectiveness for dendrimer plus ODN-1 to inhibit laser induced CNV seemed to be paralleled by the histology on the frozen eyes. At 2 months post injection, fluorescence microscopy revealed the presence of ODN-1 6-FAM within the major cellular layers of the retina (Figure 6c ). However, this signal became reduced by 4 months post injection, and at 6 months, no signal was detected in the sectioned tissue (Figure 3d ). In addition, the signal seemed to be confined to the nuclei of the cells and absent from the cytoplasmic compartment. This observation would be in keeping with our previous hypothesis that the ODN-1 inhibits transcription of VEGF by binding to dsDNA (which is confined to the nuclei) resulting in polymerase arrest. 12 Based on these data and in respect to possible treatments for CNV, we can infer that the effective lifespan (and hence the treatment interval) of ODN-1 when bound to the dendrimer to be approximately 4-6 months. Other methods of prolonging the effective life of ODNs in vivo include modifying the susceptible phosphodiester backbone into the more stable phosphorothioate (PS) form or substituting the native purines for O-methyl purines within the ODN sequence. This method of modifying the ODN structure has been employed by others to improve the efficacy of ODN therapies in diseases such as cancer, 18 but these techniques were not without problems and limitations. 19 Other studies using ODNs to control CNV, such as the aptamer Figure 6 Flow diagrams of the experimental design. Rats from group one (a) were used to establish the longevity and efficacy of the dendrimer plus ODN-1 conjugate in comparison to eyes injected with ODN-1 alone. Group 2 rats (b) were used to determine the uptake and distribution of each treatment.
Dendrimer delivery of oligonucleotides into eye's RJ Marano et al EY001, 15, 20, 21 have provided encouraging initial reports with up to 87.5% of patients in the trial showing improved or stabilized vision. However treatment, which consisted of intravitreal injections every 28 days, also resulted in side effects such as vitreous floaters, anterior chamber inflammations and ocular irritation. To resist the effects of nucleases EY001 possessed O-methylated purines in addition to the attachment of a polyethylene glycol molecule at the 5 0 end of the sequence. However, it has not been discussed if these were the cause of the adverse side effects. Other studies have shown dendrimers to possess toxic side effects both in vitro and in vivo at high doses, but the effects were minimized by optimizing the dose, chemistry and DNA:dendrimer ratio. [22] [23] [24] Although not yet tested in human trials, no inflammatory response to the injected dendrimer or to the dendrimer plus ODN-1 was observed in our study at any time using ophthalmological examination. In addition, further examination using immunohistochemistry could not detect an increase in the presence of macrophages, which are related to an inflammatory response mediated by toxicity. This may be aided by the fact that the compounds were delivered directly into the eye rather than systemically, enabling us to use minimal concentrations.
In this study, we have investigated the effectiveness of a dendrimer bound, anti-VEGF ODN in its ability to inhibit CNV in a laser-induced rodent model. Our data suggest that the effective life of dendrimer plus ODN-1 would be 4-6 months. This compares favorably with other ODN-based therapies, which require treatments every 28 days. In addition, we have explored the longterm biological effects this compound has on the rodent eye and found no evidence of adverse effects. This combination of prolonged efficacy and little or no side effects would make this combination of a dendrimermediated delivery of ODN-1 a prospective candidate as an anti-CNV therapeutic for the treatment of diseases such as exudative AMD.
Materials and methods
Experimental design
Two groups of rats were used in the course of these experiments (Figure 6a and b) . Group 1 consisted of three subgroups (a, b and c) containing 15 rats. Each subgroup was subsequently injected either with naked oligonucleotide (ODN-1) (group 1a), a dendrimer plus ODN-1 conjugate (group 1b) or dendrimer alone (group 1c) into the vitreous of both eyes. In addition to this, group 2 consisted of two subgroups of four rats, which were injected with either ODN-1 6-FAM (subgroup 2a) or a dendrimer plus ODN-1 6-FAM conjugate (subgroup 2b) into the vitreous of both eyes. The synthesis of the dendrimer used (dendrimer 4) has been previously described 13 and is shown in Figure 7 . At 2 months post injection, 6-9 lesions were introduced to both eyes of five rats from subgroups 1a, b and c by laser photocoagulation. At 2 weeks after the lesions were administered, the extent of neovascularization was documented using CFP and FA. This procedure was repeated at 4 and 6 months post injection on a further five rats from groups 1a, b and c for each time point. In additions to this, one rat from groups 2a and 2b were euthanized and the eyes enucleated at 2 weeks, 2 months, 4 months and 6 months post injection and the eyes frozen in optimal cutting temperature (OCT) compound for sectioning or used as a whole mount. The sections and whole mounts were viewed using fluorescence microscopy to determine the uptake and distribution of ODN-1 6-FAM and the dendrimer plus ODN-1 6-FAM conjugate within the retinal tissue both in the initial stage and progressively throughout the course of the experiments. Controls consisting of one rat injected with vehicle were used for each of the time points.
Injections
All animal experiments were performed in accordance with ARVO Statement of the Use of Animals in Vision and Ophthalmic Research. Preinjection, animals were anaesthetized with a mixture of ketamine (50 mg/kg body weight) and xylazine (8 mg/kg body weight). Tears Naturale s (Alcon, Frenches Forrest, NSW, Australia) were applied topically to prevent eyes from drying during the injection process.
In all, 2 ml of a 75 mM concentration of ODN-1, dendrimer plus ODN-1 complex (relative to ODN-1), dendrimer without ODN-1, 6-FAM-tagged ODN-1 (ODN-1 6-FAM ) or dendrimer plus ODN-1 6-FAM complex was injected into the vitreous of both eyes of 8-week-old rcs/rdy + -pigmented rats.
Induction of CNV by krypton laser photocoagulation
Krypton laser irradiation (647.1 nm, Coherent Radiation System, CA, USA) was delivered to both eyes of each animal from group 1a, 1b and 1c through a Zeiss slit lamp with a hand-held coverslip serving as a contact lens. A total of 6-9 laser burns were applied to each eye surrounding the optic nerve at the posterior pole at a setting of 100 mM diameter, 0.1 s duration and 150 mW intensity.
Quantization of CNV
The formation and extent of CNV in the eye using this model was monitored using CFP and FA. Anaesthetized animals were injected intraperitoneally with 0.3-0.4 ml of 10% sodium fluorescein and the eyes photographed using fluorescence fundus photography. The extent of fluorescein leakage was calculated using a previously described densitometry method. 25 The mean score between paired dendrimer/ODN-1 complexes and dendrimer without ODN-1 were compared by ANOVA with a post hoc Tuckey/Kramer analysis. Differences were considered significant at Po0.05. Dendrimer delivery of oligonucleotides into eye's RJ Marano et al
In addition to the densitometry method, the extent of CNV was evaluated by measuring the lesion thickness. Serial paraffin sections were stained with H&E and digital microscopic images were acquired using a video camera (Olympus DP70, Tokyo, Japan). The sections containing the largest area of subretinal membrane for each lesion was identified. Using a measurement technique that accounts for the position and angle of sections, 26 the thickness from the bottom of the choroidal layer to the top of the subretinal membrane was recorded using the software Carnoy. 27 The level of NV was determined by the B/C ratio, where B refers to the maximum thickness of the lesion and C is the thickness of the normal RPE-choroidal layers adjacent to the lesion. The results were analyzed using ANOVA with a post hoc Dunnett's test after pooling the results from the vehicleinjected control samples. Results were considered significant at Po0.05.
Histology
All rats were euthanized 2 days following photography and the eyes enucleated. Eyes that were injected with ODN-1 6-FAM and dendrimer plus ODN-1 6-FAM were frozen in OCT compound, sectioned at a thickness of 5 mm using a Leica CM 3050s cryostat (Leica Instruments, Wetzlar, Germany) and transferred to a silanated microscope slide. Sections were fixed by incubating in ice-cold methanol for 5 min followed by rehydration by progressive 5 min incubations in 100, 90 and 70% ethanol. Autofluorescence was quenched by a 5-min incubation in 0.5% Sudan black solution in 70% ethanol. The sections were viewed and documented by fluorescence microscopy using an Olympus microscope (Olympus, Tokyo, Japan) and an Olympus DP70 video camera. Similarly, paraffin-embedded eyes were sectioned at a thickness of 5 mm using a Reichert-Jung microtome (Leica Instruments) and transferred to silanated microscope slides. These were either subjected to H&E staining as previously described or used for immunohistochemistry studies.
Immunohistochemistry
Immunohistochemistry was performed on both frozen and paraffin-embedded sections. Paraffin sections were rehydrated by 5 min sequential incubations in xylene ( Â 3), 100, 90 and 70% ethanol with a final incubation in distilled water. Frozen sections were hydrated as detailed above. Once rehydrated, all sections were treated in the same manner. Antigen retrieval was performed by a 30-min incubation in 20 mg/ml of proteinase K. The sections were blocked by a 60-min incubation in whole rabbit serum followed by 2 Â 5 min washes in a solution of PBS supplemented with 0.1% tween (PBS-T). The primary antibody (mouse anti rat CD68) (Immunotech, Marseille, France) was applied to the sections and incubated at room temperature for 1 h followed by 2 Â 5 min washes in PBS-T. The secondary antibody (goat anti mouse alkaline phosphatase conjugate, Sigma-Aldrich, St Louis, MO, USA) was applied and the sections incubated for 1 h at room temperature followed by 2 Â 5 min washes in PBS-T. Cells were then stained for 30 min using western bluet (Promega, Madison, WI, USA) substrate, which yields a blue/ purple color. Sections were then mounted in Ultramount media (Scot Scientific, Malaga, WA, Australia) for evaluation using microscopy.
